J.P. Morgan is recapping script data from Amylin Pharmaceuticals, Inc. AMLN.
“In this note, we recap key script data in the diabetes drug landscape with a focus on the GLP-1 market,” J.P. Morgan writes. “Specifically for the week ended June 3, Byetta TRx was low and NRx was in line with the group while Victoza recorded the lowest NRx and TRx growth after a strong jump last week. Overall, total wk/wk GLP-1 script growth was weak.”
Amylin Pharmaceuticals closed Monday at $12.05.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in